Orgenesis subsidiary MaSTherCell Global to build new facility in Belgium for cell and gene therapy manufacturing

The new 61,354 square foot production facility in Gosselies Biopark, in Belgium is expected to triple the company’s European capacity

Orgenesis Inc's subsidiary MaSTherCell Global's production facility
The company’s subsidiary MaSTherCell Global is a leading cell and gene therapy global contract development and manufacturing organization

Orgenesis Inc (NASDAQ:ORGS) said Monday that it plans to build an advanced production site in Belgium to help its subsidiary MaSTherCell Global manufacture commercially approved cell and gene therapy products.

The company signed a lease agreement for a 61,354 square foot space in a building located within Gosselies Biopark, in Belgium.

The new commercial facility, expected to be up-and-running by early-2021 will triple MaSTherCell Global’s capacity. The facility will include industry 4.0 precepts such as “software integration, intelligent equipment and integrated processes” which will provide cost-effective manufacturing solutions for cell and gene therapy customers.

DEEP DIVE: Orgenesis leads the charge at an exciting time for cell therapy

Once the new commercial facility is operational, the current facility, also located within the Gosselies Biopark biotech cluster, will shift its focus to industrial manufacturing process development and early to mid-stage, clinically-focused cell and gene therapy products.

“We are excited to launch this new facility, which will significantly enhance our capacity to meet growing demand,” said Orgenesis CEO Vered Caplan in a statement. “This new facility will provide our customers unparalleled manufacturing capabilities and a strong competitive advantage. We believe this facility, in addition to our current global capabilities, will also help patients by providing greater access to life saving therapies.”

Expansion mode

MaSTherCell Global is a leading cell and gene therapy global contract development and manufacturing organization, or CDMO.

“As a leading CDMO, MaSTherCell is working hard to address the lack of commercial manufacturing capacity, especially in Europe,” said Dr Denis Bedoret, president at MaSTherCell Global. “With this facility, we aim to be the first CDMO in Europe to have a dedicated area for large-scale commercial manufacturing.”

The new production facility will create local employment.

“It will create several hundred jobs and allow us to tap into local Belgian expertise to train our teams within the heart of Europe, in support of our international recruitment goals,” said Eric Mathieu, chief operating officer of MaSTherCell’s Belgium operations.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Orgenesis

Price: 3.52 USD

Market: NASDAQ
Market Cap: $56.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...



Orgenesis gets Orphan Drug designation to treat severe diabetes

Orgenesis Inc (NASDAQ:ORGS) Chief Scientific Officer Dr. Sarah Ferber tells Proactive Investors the FDA has granted Orphan Drug designation to its Autologous Insulin Producing (AIP) cells as a cell-replacement therapy for the treatment of severe diabetes following a pancreatectomy, a surgical...

on 06/28/2019

2 min read